Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2.
|
31823521 |
2020 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity.
|
30842158 |
2019 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody (mAb), is a novel targeted therapy for the treatment of patients with oral cancer.
|
30333889 |
2018 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
|
28841839 |
2017 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, CMP and its ingredient cordycepin can inhibit tumor growth and malignant transformation in a mouse model for oral cancer via inhibition of EGFR- and IL-17RA-signaling and enhancement of anti-tumor immunity.
|
29212184 |
2017 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer.
|
28782189 |
2017 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence microscopy, real-time PCR, Western blot analysis, and in vivo bioimaging of mice containing orthotopic xenograft tumors were used to examine the ability of the dual peptide carrier to mediate specific delivery of bioactive siRNAs into EGFR-overexpressing oral cancer cells/tissues.
|
28797448 |
2017 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
To test if the epidermal growth factor receptor inhibitor erlotinib would reduce oral cancer development in patients with high-risk OPLs defined by specific loss of heterozygosity (LOH) profiles.
|
26540028 |
2016 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer.
|
26462152 |
2015 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting Ley on EGFR could have a potential therapeutic effect on oral cancer.
|
25799278 |
2015 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of EGFR results in a poor prognosis in oral cancer and its activation is associated with the malignant phenotype, inhibition of apoptosis and increased metastatic potential.
|
24692681 |
2014 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates this approach as an effective way to reduce the incidence of oral cancer, and supports investigation of this strategy in the clinic.
|
24412287 |
2014 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we hypothesized that FOXO1 might be crucial in quercetin-induced growth inhibition in EGFR-overexpressing oral cancer.
|
23618529 |
2013 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
N-acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG box-containing protein 1 (HBP1) signaling pathway in invasive oral cancer.
|
22944050 |
2013 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance.
|
23806066 |
2013 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Aim of the present work is to define the key-role of EGFR in oral cancer prognosis.
|
22825335 |
2012 |
Malignant neoplasm of mouth
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area.
|
21284055 |
2011 |
Malignant neoplasm of mouth
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer.
|
21304522 |
2011 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunostaining showed a significant association between EGFR expression and aberrant accumulation of beta-catenin in oral cancer.
|
20302655 |
2010 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The overexpression of EGFR mRNA, p50:p50/NF-kappaB homodimer formation, together with overexpression of pERK and c-Fos proteins in this study suggests an interesting cross talk between AP-1 and NF-kappaB pathways in oral cancers.
|
19653276 |
2010 |
Malignant neoplasm of mouth
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This perspective on the report by Benchekroun et al. in this issue of the journal (beginning on page 800) examines new studies of factors in the epidermal growth factor receptor (EGFR) axis (including copy number alterations at the EGFR locus) that potentially predict the development of oral cancer; this work was conducted in a chemoprevention trial cohort of patients with oral premalignant lesions.
|
20570884 |
2010 |
Malignant neoplasm of mouth
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data indicate that an increased EGFR gene copy number is common in and associated with OSCC development in patients with OPLs expressing high EGFR, particularly OSCC developing at the site of a high-expression OPL; they also suggest that EGFR inhibitors may prevent oral cancer in patients with OPLs having an increased EGFR gene copy number.
|
20570883 |
2010 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family, which is expressed or highly expressed in a variety of solid tumors, including oral cancers.
|
16799709 |
2006 |
Malignant neoplasm of mouth
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features.
|
15791567 |
2005 |
Malignant neoplasm of mouth
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Carriers of > or = 16 CA repeats in EGFR showed a 1.9-fold increased risk for oral cancer (OR=1.9, 95% CI=1.0-3.5).
|
15864136 |
2005 |